Avicenna Pharmaceuticals

Avicenna Pharmaceuticals is a clinical-stage biotechnology company specializing in the design and development of site-specific antibody-drug conjugates (ADCs) for oncology indications. The company's core technology centers on a proprietary conjugation platform that enables the production of homogeneous ADCs with optimized drug-to-antibody ratios (DAR). By improving the structural stability of these conjugates, Avicenna aims to enhance the therapeutic index of cytotoxic payloads, reducing systemic side effects while increasing potency against tumors. The lead program, AV-201, is an ADC targeting HER2-expressing malignancies, designed to address unmet needs in breast and gastric cancers.